KEAP1 and neoplasm: STK11, KEAP1, and SMARCA4 are tumor suppressors in lung tissue and mutations in those genes correlate with significantly worse outcomes for patients with NSCLC, particularly after ICI therapy [14, 16, 26, 27, 33, 34].